Research graph
References from The evolving role of nuclear medicine in differentiating pseudoprogression from tumor progression in gliomas. Local targets link to admitted publications; unresolved targets remain external evidence.
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
10.1007/s11060-009-9809-4 · 2009 · External reference
Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma
10.1001/jama.2017.18718 · 2017 · External reference
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults
10.3174/ajnr.a8396 · 2024 · External reference
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18 F]FDG: version 1.0
10.1007/s00259-018-4207-9 · 2019 · External reference
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
10.1016/s1470-2045(23)00525-9 · 2024 · External reference
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
10.1016/s1470-2045(25)00193-7 · 2025 · External reference
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
10.1002/cncr.23562 · 2008 · External reference
Pseudoprogression of brain tumors
10.1002/jmri.26171 · 2018 · External reference
RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults
10.1200/jco.23.01059 · 2023 · External reference
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma
10.3174/ajnr.a2397 · 2011 · External reference
Perioperative imaging predictors of tumor progression and pseudoprogression: a systematic review
10.1016/j.critrevonc.2024.104445 · 2024 · External reference
Impact of imaging measurements on response assessment in glioblastoma clinical trials
10.1093/neuonc/nou286 · 2014 · External reference
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
10.1016/s1470-2045(08)70125-6 · 2008 · External reference
Glioblastoma: epidemiology and imaging-based review
2025 · External reference
Image-based re-evaluation of the JCOG0911 study focusing on tumor volume and survival, disease progression diagnosis, and radiomic prognostication for newly diagnosed glioblastoma
10.2463/mrms.mp.2024-0103 · 2025 · External reference
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology
10.1007/s11604-025-01821-6 · 2025 · External reference
The state-of-the-art PET tracers in glioblastoma and high-grade gliomas and implications for theranostics
10.1016/j.cpet.2024.09.009 · 2025 · External reference
PET imaging of gliomas: status quo and quo vadis?
10.1093/neuonc/noae078 · 2024 · External reference
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
10.1093/neuonc/now058 · 2016 · External reference
Flare phenomenon in o-(2-18f-fluoroethyl)-l-tyrosine pet after resection of gliomas
10.2967/jnumed.119.238568 · 2020 · External reference
Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: a report of the PET/RANO group
2024 · External reference
Clinical impact of [18F]FET-PET/CT in differentiating treatment-associated changes and tumor progression in adult-type diffuse gliomas
2026 · External reference
Comparison of visual and semiquantitative analysis of 18F-FDOPA- PET/CT for recurrence detection in glioblastoma patients
10.1093/neuonc/not166 · 2014 · External reference
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): methodological application in [18F]-FDOPA PET imaging
10.1186/s13550-025-01239-1 · 2025 · External reference
Distinguishing progression from pseudoprogression in glioblastoma using 18F-fluciclovine PET
10.2967/jnumed.122.264812 · 2023 · External reference
Defining treatment-related adverse effects in patients with glioma: distinctive features of pseudoprogression and treatment-induced necrosis
10.1634/theoncologist.2020-0085 · 2020 · External reference
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
10.1007/s11060-015-1774-5 · 2015 · External reference
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence
10.3174/ajnr.a4218 · 2015 · External reference
The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma
2015 · External reference
Dynamic11 c-methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence
10.3390/cancers13194777 · 2021 · External reference
Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI
10.1016/j.ejrad.2018.04.003 · 2018 · External reference
18F-FET PET imaging in differentiating glioma progression from treatment-related changes: a single-center experience
10.2967/jnumed.119.234757 · 2020 · External reference
Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression
10.1186/s13550-020-00645-x · 2020 · External reference
Sequential implementation of DSC-MR perfusion and dynamic [18 F] FET PET allows efficient differentiation of glioma progression from treatment-related changes
10.1007/s00259-020-05114-0 · 2021 · External reference
Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with posttreatment glioma
10.3389/fnume.2026.1762984 · 2026 · External reference
[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial
10.1186/s13063-025-08921-8 · 2025 · External reference
Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18 F]fluoroethyl)-L-Tyrosine PET
10.1158/1078-0432.ccr-15-1334 · 2016 · External reference
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions
10.1007/s00259-024-06720-y · 2024 · External reference
Differentiating high-grade glioma progression from treatment-related changes with dynamic [18 F]FDOPA PET: a multicentric study [Internet]
10.1007/s00330-022-09221-4 · 2023 · External reference
Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas
10.1007/s00259-019-04509-y · 2020 · External reference
18F-FDOPA PET for the noninvasive prediction of glioma molecular parameters: a radiomics study
10.2967/jnumed.120.261545 · 2022 · External reference
Advances in neuro-oncology imaging
10.1038/nrneurol.2017.44 · 2017 · External reference
Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein
10.2967/jnumed.118.210443 · 2018 · External reference
Fibroblast activation protein expression in the tumor microenvironment is crucial in survival prediction and differentiation of recurrent gliomas: a head-to-head comparison of 68Ga-FAPI-04 and 18F-FET in PET/CT imaging
10.1186/s41181-025-00378-z · 2025 · External reference
Reconstruction matters: influence of EARL standards and BSREM in [18F]FET PET for distinguishing glioma progression from treatment-related changes
10.1186/s13550-026-01458-0 · 2026 · External reference
Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects
2026 · External reference
A deep learning model for distinguishing pseudoprogression and tumor progression in glioblastoma based on pre and postoperative contrast-enhanced T1 imaging
10.1016/j.radonc.2025.111111 · 2025 · External reference
Multi-Sequence MRI radiomics model for discrimination of recurrence and pseudoprogression in gliomas
10.1016/j.ejrad.2025.112508 · 2026 · External reference
Fet pet radiomics for differentiating pseudoprogression from early tumor progression in glioma patients postchemoradiation
10.3390/cancers12123835 · 2020 · External reference
Interobserver ground-truth variability limits performance of automated glioblastoma segmentation on [18F]FET PET
10.1186/s40658-025-00767-y · 2025 · External reference
Radiomics-based quantification of tumor infiltration in the nonenhancing peritumoral region on postoperative MRI is associated with survival in glioblastoma
10.1038/s41598-025-27711-5 · 2025 · External reference
Application of artificial intelligence in oncologic molecular PET-imaging: a narrative review on beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and other less-commonly used radiotracers
10.1053/j.semnuclmed.2024.01.002 · 2024 · External reference
CMRO2 (DSC-PW) perfusion parameter helps to distinguish between progression and pseudoprogression in patients with glioblastoma
10.1007/s11547-025-02103-x · 2025 · External reference
Radionuclide-based nanotechnologies in brain tumors: an updated overview
10.1007/s40336-025-00711-1 · 2025 · External reference
Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma
10.1001/jama.2017.18718 · ExternalCitation · doi-reference
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
10.1002/cncr.23562 · ExternalCitation · doi-reference
Pseudoprogression of brain tumors
10.1002/jmri.26171 · ExternalCitation · doi-reference
Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18 F]FDG: version 1.0
10.1007/s00259-018-4207-9 · ExternalCitation · doi-reference
Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas
10.1007/s00259-019-04509-y · ExternalCitation · doi-reference
Sequential implementation of DSC-MR perfusion and dynamic [18 F] FET PET allows efficient differentiation of glioma progression from treatment-related changes
10.1007/s00259-020-05114-0 · ExternalCitation · doi-reference
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions
10.1007/s00259-024-06720-y · ExternalCitation · doi-reference
Differentiating high-grade glioma progression from treatment-related changes with dynamic [18 F]FDOPA PET: a multicentric study [Internet]
10.1007/s00330-022-09221-4 · ExternalCitation · doi-reference
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
10.1007/s11060-009-9809-4 · ExternalCitation · doi-reference
Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
10.1007/s11060-015-1774-5 · ExternalCitation · doi-reference
CMRO2 (DSC-PW) perfusion parameter helps to distinguish between progression and pseudoprogression in patients with glioblastoma
10.1007/s11547-025-02103-x · ExternalCitation · doi-reference
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology
10.1007/s11604-025-01821-6 · ExternalCitation · doi-reference
Radionuclide-based nanotechnologies in brain tumors: an updated overview
10.1007/s40336-025-00711-1 · ExternalCitation · doi-reference
The state-of-the-art PET tracers in glioblastoma and high-grade gliomas and implications for theranostics
10.1016/j.cpet.2024.09.009 · ExternalCitation · doi-reference
Perioperative imaging predictors of tumor progression and pseudoprogression: a systematic review
10.1016/j.critrevonc.2024.104445 · ExternalCitation · doi-reference
Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI
10.1016/j.ejrad.2018.04.003 · ExternalCitation · doi-reference
Multi-Sequence MRI radiomics model for discrimination of recurrence and pseudoprogression in gliomas
10.1016/j.ejrad.2025.112508 · ExternalCitation · doi-reference
A deep learning model for distinguishing pseudoprogression and tumor progression in glioblastoma based on pre and postoperative contrast-enhanced T1 imaging
10.1016/j.radonc.2025.111111 · ExternalCitation · doi-reference
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
10.1016/s1470-2045(08)70125-6 · ExternalCitation · doi-reference
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
10.1016/s1470-2045(23)00525-9 · ExternalCitation · doi-reference
Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas
10.1016/s1470-2045(25)00193-7 · ExternalCitation · doi-reference
Advances in neuro-oncology imaging
10.1038/nrneurol.2017.44 · ExternalCitation · doi-reference
Radiomics-based quantification of tumor infiltration in the nonenhancing peritumoral region on postoperative MRI is associated with survival in glioblastoma
10.1038/s41598-025-27711-5 · ExternalCitation · doi-reference
Application of artificial intelligence in oncologic molecular PET-imaging: a narrative review on beyond [18F]F-FDG Tracers Part II. [18F]F-FLT, [18F]F-FET, [11C]C-MET and other less-commonly used radiotracers
10.1053/j.semnuclmed.2024.01.002 · ExternalCitation · doi-reference
PET imaging of gliomas: status quo and quo vadis?
10.1093/neuonc/noae078 · ExternalCitation · doi-reference
Comparison of visual and semiquantitative analysis of 18F-FDOPA- PET/CT for recurrence detection in glioblastoma patients
10.1093/neuonc/not166 · ExternalCitation · doi-reference
Impact of imaging measurements on response assessment in glioblastoma clinical trials
10.1093/neuonc/nou286 · ExternalCitation · doi-reference
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
10.1093/neuonc/now058 · ExternalCitation · doi-reference
Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18 F]fluoroethyl)-L-Tyrosine PET
10.1158/1078-0432.ccr-15-1334 · ExternalCitation · doi-reference
[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial
10.1186/s13063-025-08921-8 · ExternalCitation · doi-reference
Use of static and dynamic [18F]-F-DOPA PET parameters for detecting patients with glioma recurrence or progression
10.1186/s13550-020-00645-x · ExternalCitation · doi-reference
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): methodological application in [18F]-FDOPA PET imaging
10.1186/s13550-025-01239-1 · ExternalCitation · doi-reference
Reconstruction matters: influence of EARL standards and BSREM in [18F]FET PET for distinguishing glioma progression from treatment-related changes
10.1186/s13550-026-01458-0 · ExternalCitation · doi-reference
Interobserver ground-truth variability limits performance of automated glioblastoma segmentation on [18F]FET PET
10.1186/s40658-025-00767-y · ExternalCitation · doi-reference
Fibroblast activation protein expression in the tumor microenvironment is crucial in survival prediction and differentiation of recurrent gliomas: a head-to-head comparison of 68Ga-FAPI-04 and 18F-FET in PET/CT imaging
10.1186/s41181-025-00378-z · ExternalCitation · doi-reference
RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults
10.1200/jco.23.01059 · ExternalCitation · doi-reference
Defining treatment-related adverse effects in patients with glioma: distinctive features of pseudoprogression and treatment-induced necrosis
10.1634/theoncologist.2020-0085 · ExternalCitation · doi-reference
Image-based re-evaluation of the JCOG0911 study focusing on tumor volume and survival, disease progression diagnosis, and radiomic prognostication for newly diagnosed glioblastoma
10.2463/mrms.mp.2024-0103 · ExternalCitation · doi-reference
Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein
10.2967/jnumed.118.210443 · ExternalCitation · doi-reference
18F-FET PET imaging in differentiating glioma progression from treatment-related changes: a single-center experience
10.2967/jnumed.119.234757 · ExternalCitation · doi-reference
Flare phenomenon in o-(2-18f-fluoroethyl)-l-tyrosine pet after resection of gliomas
10.2967/jnumed.119.238568 · ExternalCitation · doi-reference
18F-FDOPA PET for the noninvasive prediction of glioma molecular parameters: a radiomics study
10.2967/jnumed.120.261545 · ExternalCitation · doi-reference
Distinguishing progression from pseudoprogression in glioblastoma using 18F-fluciclovine PET
10.2967/jnumed.122.264812 · ExternalCitation · doi-reference
Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma
10.3174/ajnr.a2397 · ExternalCitation · doi-reference
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence
10.3174/ajnr.a4218 · ExternalCitation · doi-reference
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults
10.3174/ajnr.a8396 · ExternalCitation · doi-reference
Rethinking dynamics: static amino acid PET parameters vs. dynamic amino acid PET parameters for the detection of tumor progression in patients with posttreatment glioma
10.3389/fnume.2026.1762984 · ExternalCitation · doi-reference
Fet pet radiomics for differentiating pseudoprogression from early tumor progression in glioma patients postchemoradiation
10.3390/cancers12123835 · ExternalCitation · doi-reference
Dynamic11 c-methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence
10.3390/cancers13194777 · ExternalCitation · doi-reference
